Thrombolex Names Michael Cerminaro as CEO, Succeeding Marvin Woodall

July 15, 2022—Thrombolex announced that its Board of Directors has named Michael Cerminaro as Chief Executive Officer (CEO) of the company effective July 13, 2022. Mr. Cerminaro will also retain his current title of President. Marvin Woodall, currently Chairman and CEO, will serve as Executive Chairman and transition the CEO role to Mr. Cerminaro, who is currently President and Chief Operating Officer.

Mr. Woodall and Mr. Cerminaro are cofounders of Thrombolex and have been members of the Board of Directors since the inception of the company in 2016.

According to Thrombolex, Mr. Woodall led the company from early-stage startup to commercial stage innovator with therapies to treat arterial and venous thromboembolic (VTE) disease. A primary focus of R&D and clinical investment under Mr. Woodall’s leadership has been the development of a platform technology that has demonstrated best-in-class clinical data and exceptional early safety.

The company currently has seven FDA-cleared devices that are all based on the Bashir endovascular catheter platform technology for pharmacomechanical catheter-directed thrombolysis in patients with arterial and VTE disease.

“My decision to transition the CEO role to Michael has come at the right time for the company as our organization is delivering strong progress and is positioned for continued success,” commented Mr. Woodall in the Thrombolex press release. He continued, “It has been an honor and privilege to lead Thrombolex as Chairman and CEO, and I am pleased to serve as Executive Chairman to help oversee the company’s ongoing mission to bring innovative therapies to people all over the world. I am also immensely proud of how we have upheld the company’s legacy of delivering clinical therapies to address one of the most urgent, unmet clinical needs, treatment of arterial and VTE disease.”

Mr. Woodall concluded, “I have the utmost confidence in Michael to lead Thrombolex as the company’s next CEO and I am confident that the future of Thrombolex is in very capable hands.”

Paul Stewart, an independent member of the company’s Board of Directors, expressed gratitude to Mr. Woodall on behalf of the Board, stating, “Marv’s leadership and accomplishments since inception have been extraordinary and Thrombolex is much stronger, more diverse, and much better positioned to succeed in today’s evolving health care marketplace due to his exceptional stewardship.”

Mr. Steward continued, “Given Michael’s deep commitment to the company’s mission and his ability to effectively lead, collaborate, and create value, the Board of Directors are highly confident in his ability to drive continued rapid commercialization of the Bashir family of pharmaco-mechanical endovascular catheters.”

Finally, Mr. Cerminaro stated in the press release, “I am honored to serve as Thrombolex’s next CEO. Our company has been a medical device innovator with a robust pipeline of transformational and novel therapies. I have had the pleasure of working closely with Marv since we cofounded Thrombolex and thank him for his outstanding leadership and accomplishments. I am pleased that I will continue to benefit from his continued guidance and insights moving forward.”

He added, "Above all I am excited to be leading an incredibly talented and experienced team of industry professionals that continue to be guided by our mission to save lives and improve outcomes for every patient treated with our innovative technology. I also look forward to working closely with Marv and the broader executive management team, in my role as CEO, to write Thrombolex’s next chapter."